

# Hepatitis Drugs and Vaccines: World Market 2013-2023

<https://marketpublishers.com/r/H0F51E5D826EN.html>

Date: June 2013

Pages: 197

Price: US\$ 2,635.00 (Single User License)

ID: H0F51E5D826EN

## Abstracts

### Your guide to sales outlooks and R&D for hepatitis treatments

Where are hepatitis medicines going? Visiongain's updated report predicts revenues there from 2013 to 2023. It also explains trends in that business and technology - with prospects and opportunities - to help your work.

In that study you gain sales forecasts at overall world market, submarket, product, and national level. See what's happening. Also discover what has most growth potential.

Read on, then, to explore that industry and see what its future market could be worth.

### Forecasts to 2023 and other analyses show you commercial potentials

Besides revenue forecasting, our new work shows historical data, growth rates, and market shares. You discover original quantitative and qualitative analysis, seeing business outlooks and research developments (R&D). You also get 77 tables, 66 charts, and an interview.

Is finding data for anti-hepatitis products a challenge? Avoid falling behind. You can now stay ahead in knowledge, benefiting your research, analyses, and decisions. Also save time.

There you investigate the future of hepatitis medicine. You discover what's happening and see where the money lies. Finding that antiviral data just got easier.

Anyhow, the following sections show what you get in our new research and analysis.

## **Discover prospects for the world market and submarkets**

Our new report shows revenue to 2023 for the overall world market. It also shows you individual forecasts of four hepatitis treatment submarkets:

Oral antivirals

Interferons

Vaccines

Other agents.

How will the hepatitis drugs and vaccines market expand? Which parts will most prosper? There you assess potential for sales and revenue growth.

Also our study discusses what stimulates and restrains that market. That analysis helps you identify potential and find ways for your business to benefit.

You also find revenue predictions for brands.

## **See forecasts for 10 leading anti-hepatitis products**

How will those antiviral brands perform to 2023 at world level? Our study forecasts individual revenues of 10 top products:

Baraclude

Zeffix

Hepsera

Viread

Tyzeka

Engerix-B/Havrix/Twinrix/Fendrix

Pegasys

Incivek

PegIntron

Victrelis.

There you discover how high sales can go, to 2023, finding products and years with highest predicted growth and revenues. Also you compare competitors. You see what's happening, then, understanding trends, competition, challenges, and opportunities.

Our report also divides its overall world forecast into geographical regions.

### **What prospects for regions and countries?**

Developments worldwide expand the hepatitis products market, especially rising demand for medicines in emerging countries. China, India, Russia, and Brazil underpin revenue growth.

In developed and developing countries, opportunities for pharmaceutical companies will occur from 2013 to 2023. See where and how.

Our analyses show you individual revenue forecasts to 2023 for 11 national markets:

United States (US)

Japan

EU leaders - Germany, France, the UK, Italy, and Spain (EU5)

BRIC countries - Brazil, Russia, India, and China.

There you discover progress and outlooks. In particular, drug and vaccine launches from 2013 to 2023 will change medical prescribing and the commercial landscape. See how.

## **Research and development - assess innovation, trends, and possibilities**

What about R&D - pipelines for new drugs and vaccines? You assess trends there, including these:

Cyclophilin inhibition

Protease inhibition

All-oral agents

Agents with potential roles in hep-C/HIV co-infection

Nucleoside and non-nucleoside polymerase inhibition

Therapeutic vaccines

Combination regimens.

R&D for hepatitis medicine holds strength, variety, and promise. You assess innovations there, hearing about developments and finding their significance. Discover progress.

For large companies and specialty pharma firms there exist many opportunities. Our study explains, discussing progress to help your work. See, then, what the future holds.

## **Prominent companies and 2017 market value**

What happens next? From 2013, new treatments hold great potential for investment, technological advances and high revenues. Our report predicts the world market for anti-hepatitis drugs and vaccines will reach \$15.25bn in 2017, and expand further to 2023.

Our work shows you what activities, technologies, and organisations there hold potential. Its analyses cover prominent companies, including these:

Roche

GSK

Bristol-Myers Squibb

Merck & Co.

Vertex Pharmaceuticals

Gilead Sciences

Novartis.

Prospects for R&D are strong, and from 2013 there will arise many opportunities. Our analysis shows you possibilities, helping you stay ahead.

### **Nine ways Hepatitis Drugs and Vaccines: World Market 2013-2023 helps you**

To sum up, our investigation gives you the following knowledge:

Revenue to 2023 of the world market for anti-hepatitis products - discover that industry's overall sales potential

Revenues to 2023 for 4 world-level submarkets - investigate the potential of its components, finding the most promising places for investments and revenues

Revenues to 2023 for 10 products - find sales outlooks for top brands, seeing how they can compete and succeed

Forecasts to 2023 for 11 national markets in the Americas, Europe, and Asia - discover the best countries for revenues and potential growth

Assessments of 11 companies - hear about participants' activities, capabilities, results, and outlooks

Review of R&D - explore progress in research and development, finding technological and medical possibilities

Competition and opportunities - investigate what shapes that market's future,

including ways to develop business

Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and get advantages

Prospects for established competitors and firms seeking to enter that sector - explore needs, practices and outlooks for future success.

### **You gain information found nowhere else**

That work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.

Assess the potential of those antiviral agents now, seeing what you can gain.

Hepatitis medicine - see commercial prospects from 2013 by ordering now

Our new study lets you find data, trends, opportunities, and sales predictions for hepatitis prevention and treatment. Avoid missing out - please order our report now.

## Contents

### 1. EXECUTIVE SUMMARY

- 1.1 Hepatitis Treatments and Vaccines: World Market Overview
- 1.2 Chapter Breakdown
- 1.3 Research and Analysis Methods

### 2. INTRODUCTION TO HEPATITIS AND ITS TREATMENTS

- 2.1 What is Hepatitis?
- 2.2 Diagnosing Hepatitis: The Asymptotic Nature of the Disease
- 2.3 How is Hepatitis Classified?
  - 2.3.1 Hepatitis A
  - 2.3.2 Hepatitis B
  - 2.3.3 Hepatitis C
  - 2.3.4 Hepatitis D
  - 2.3.5 Hepatitis E
- 2.4 Risk Factors for Hepatitis
- 2.5 Incidence and Prevalence Patterns in Hepatitis
- 2.6 Hepatitis: Treatment and Prevention
  - 2.6.1 Antivirals: Inhibiting Viral Replication
    - 2.6.1.1 Reverse Transcriptase Inhibitors
    - 2.6.1.2 Protease Inhibitors
  - 2.6.2 Interferons: Dual Mode of Action
    - 2.6.2.1 Combination Therapy: Treatment with Interferon and Antivirals
  - 2.6.3 Vaccines: The Immunotherapeutic Approach
    - 2.6.3.1 Hepatitis E Vaccine: Raising Hopes for an Overlooked Subtype

### 3. WORLD HEPATITIS TREATMENTS AND VACCINES MARKET, 2013-2023

- 3.1 The Hepatitis Treatments and Vaccines Market, 2012
  - 3.1.1 The Hepatitis Treatment Market by Indication, 2012
- 3.2 The Hepatitis Treatments and Vaccines Market: Revenue Forecast, 2013-2023
  - 3.2.1 Rising Awareness and Screening: Expanding Treatment Population
  - 3.2.2 Generic Competition in the Hepatitis B Treatment Market
  - 3.2.3 Biosimilar Interferons: A New Era in Hepatitis Treatment?
  - 3.2.4 Direct-Acting Antivirals (DAAs): A Change in Therapeutic Landscape
- 3.3 Oral Antivirals Submarket, 2012

- 3.3.1 DAAs in Hepatitis B
- 3.3.2 DAAs in Hepatitis C
- 3.3.3 Oral Antivirals Submarket: Revenue Forecast, 2013-2023
- 3.3.4 Strong Developmental Pipeline to Drive Market Growth
- 3.3.5 All-Oral Treatments for Hepatitis C: Improving Tolerability
- 3.4 Interferons Submarket, 2012
  - 3.4.1 Standard of Care for Hepatitis C
  - 3.4.2 Drawbacks to Interferon Therapy
  - 3.4.3 Declining Revenues 2008-2011
  - 3.4.4 Interferons Submarket: Revenue Forecast, 2013-2023
  - 3.4.5 Next Generation Interferons: A Potential Advance or Lateral Move?
- 3.5 Hepatitis Vaccines Submarket, 2012
  - 3.5.1 GSK: A Dominant Global Player
  - 3.5.2 Expanding Vaccination Programmes in Emerging Markets
  - 3.5.3 Hepatitis Vaccines Submarket: Revenue Forecast, 2013-2023
- 3.6 Hepatitis Treatments and Vaccines: Submarket Shares 2012, 2018 and 2023
- 3.7 Hepatitis Treatment Market: Revenue Forecast by Indication, 2013-2023

## **4. LEADING NATIONAL HEPATITIS TREATMENTS AND VACCINES MARKETS, 2013-2023**

- 4.1 Global Prevalence of Hepatitis, 2012
  - 4.1.1 The Importance of Asia
- 4.2 Hepatitis Treatments and Vaccines Market: Regional Breakdown, 2012
- 4.3 Hepatitis Treatments and Vaccines Market: Regional Forecast, 2013-2023
- 4.4 The US
  - 4.4.1 Population Movement and Hepatitis
  - 4.4.2 Increased Screening towards Target Population
  - 4.4.3 The US: Revenue Forecast, 2013-2023
- 4.5 Leading EU Markets for Hepatitis Treatments and Vaccines
  - 4.5.1 Regional Prevalence
  - 4.5.2 EU5 Market, 2012
  - 4.5.3 EU5: Revenue Forecasts, 2013-2023
  - 4.5.4 Italy: Revenue Forecast, 2013-2023
  - 4.5.5 Spain: Revenue Forecast, 2013-2023
  - 4.5.6 Germany: Revenue Forecast, 2013-2023
  - 4.5.7 UK: Revenue Forecast, 2013-2023
  - 4.5.8 France: Revenue Forecast, 2013-2023
- 4.6 Hepatitis in Asia



#### 4.7 China

- 4.7.1 Increased Vaccination
- 4.7.2 Rising Middle Class
- 4.7.3 Hepatitis C Outbreaks
- 4.7.4 Domestic Drug and Vaccine Development
- 4.7.5 China: Revenue Forecast, 2013-2023

#### 4.8 Japan

- 4.8.1 Hepatitis B and C in Japan
- 4.8.2 Japan: Revenue Forecast, 2013-2023

#### 4.9 India

- 4.9.1 Low Awareness and Vaccination Rates
- 4.9.2 India: Revenue Forecast, 2013-2023

#### 4.10 Russia

- 4.10.1 Low Treatment Rate and High Drug Costs Limiting Market
- 4.10.2 Russia: Revenue Forecast, 2013-2023

#### 4.11 Brazil

- 4.11.1 Current Disease Prevalence
- 4.11.2 Brazil: Revenue Forecast, 2013-2023

### **5. LEADING HEPATITIS THERAPIES: MARKET PROSPECTS TO 2023**

#### 5.1 Leading Hepatitis B Therapies, 2013-2023

##### 5.2 Baraclude (Bristol-Myers Squibb)

- 5.2.1 Recent Revenue Analysis
- 5.2.2 Global Patent Challenges Will Hit Future Revenues
- 5.2.3 Baraclude: Revenue Forecast, 2013-2023

##### 5.3 Zeffix (GSK)

- 5.3.1 Recent Revenue Analysis
- 5.3.2 Increasing Drug Resistance with Continued Use
- 5.3.3 Launch of Generic Versions Will Affect Drug Revenues
- 5.3.4 Zeffix: Revenue Forecast, 2013-2023

##### 5.4 Hepsera (Gilead Sciences/GSK)

- 5.4.1 Recent Revenue Analysis
- 5.4.2 Patent Extension Approved Until 2016
- 5.4.3 Switching to Viread Will Limit Hepsera Revenues
- 5.4.4 Hepsera: Revenue Forecast, 2013-2023

##### 5.5 Viread (Gilead Sciences)

- 5.5.1 Recent Revenue Analysis
- 5.5.2 GSK Alliance: Targeting Emerging Asian Markets

- 5.5.3 Competition with Viread Pro-drugs may Harm Drug Revenues
- 5.5.4 Viread: Revenue Forecast, 2013-2023
- 5.6 Tyzeka (Novartis)
  - 5.6.1 Lack of Differentiation and Competition Affecting Market Share
  - 5.6.2 Tyzeka: Revenue Forecast, 2013-2023
- 5.7 Leading Hepatitis B Vaccines, 2013-2023
- 5.8 Engerix-B/Havrix/Twinrix/Fendrix (GSK)
  - 5.8.1 Recent Revenue Analysis
  - 5.8.2 Demand and Supply in Emerging Markets
  - 5.8.3 Pipeline Compounds Will Provide Strong Competition
  - 5.8.4 Engerix-B/Havrix/Twinrix/Fendrix: Revenue Forecast, 2013-2023
- 5.9 Leading Hepatitis C Therapies, 2013-2023
- 5.10 Pegasys (Roche)
  - 5.10.1 Recent Revenue Analysis
  - 5.10.2 Label Expansions and Lifecycle Management Strategies
  - 5.10.3 Pegasys: Revenue Forecast, 2013-2023
- 5.11 Incivek (Vertex Pharmaceuticals/J&J/Mitsubishi Tanabe)
  - 5.11.1 Recent Revenue Analysis
  - 5.11.2 Targeting Hep-C/HIV Co-Infected Patients
  - 5.11.3 Incivek in Interferon-Free Regimens
  - 5.11.4 Pipeline Competition May Affect Revenues
  - 5.11.5 Incivek: Revenue Forecast, 2013-2023
- 5.12 PegIntron (Merck & Co.)
  - 5.12.1 Recent Revenue Analysis
  - 5.12.2 Competition from Interferon Biosimilars
  - 5.12.3 Enhancing Drug Lifecycle
  - 5.12.4 PegIntron: Revenue Forecast, 2013-2023
- 5.13 Victrelis (Merck & Co.)
  - 5.13.1 Recent Revenue Analysis
  - 5.13.2 Roche Collaboration
  - 5.13.3 Product Differentiation
  - 5.13.4 Victrelis: Revenue Forecast, 2013-2023

## **6. HEPATITIS TREATMENTS AND VACCINES MARKET: LEADING PIPELINE CANDIDATES**

- 6.1 Leading Hepatitis C Pipeline Candidates, 2012
  - 6.1.1 Alisporivir (Novartis/Debiopharm): Advanced Cyclophilin Inhibitor
  - 6.1.2 BI 201335 (Boehringer Ingelheim): Fast-Tracked Protease Inhibitor

- 6.1.2.1 BI 207127 (Boehringer Ingelheim): First All-Oral Hep C Drug?
  - 6.1.3 Daclatasvir (Bristol-Myers Squibb): Potential Role in Hep-C/HIV Co-Infection?
    - 6.1.3.1 Asunaprevir (Bristol-Myers Squibb): Synergistic Effect with Daclatasvir
  - 6.1.4 GS-7977 (Sofosbuvir; Gilead Sciences): Progression to Phase III
  - 6.1.5 TMC435 (Tibotec Pharmaceuticals/Medivir): Next Generation Protease Inhibitor
    - 6.1.5.1 TMC435 in All-Oral Regimens
  - 6.1.6 Vaniprevir (Merck & Co.): Patent Security Till 2027
  - 6.1.7 ABT-450 (Abbott Laboratories): Fast-Tracked Into Phase III
  - 6.1.8 ACH-1625 (Achillion Pharmaceuticals): Playing Catch Up?
    - 6.1.8.1 ACH-2684 (Achillion Pharmaceuticals)
    - 6.1.8.2 ACH-2928 (Achillion Pharmaceuticals)
  - 6.1.9 ChronVac-C (ChronTech Pharma/Inovio Pharmaceuticals): Therapeutic Vaccine in Phase II Trials
  - 6.1.10 Danoprevir (Roche): Testing Out Combination Regimens
  - 6.1.11 GI-5005 (GlobelImmune): Yeast-based Hep C Vaccine
  - 6.1.12 IDX184 (Idenix Pharmaceuticals): Development Ceased
  - 6.1.13 INX-189 (Bristol-Myers Squibb): Cardiovascular Effects May Halt Development
  - 6.1.14 Locteron (Biolex): Controlled Release Formulation
  - 6.1.15 Peginterferon Lambda-1a (Bristol-Myers Squibb): Improved Side Effect Profile
  - 6.1.16 R7128 (Roche/Pharmasset): Broad Spectrum Treatment
  - 6.1.17 SCY-635 (SCYNEXIS)
  - 6.1.18 Setrobuvir (Roche): Fast-Tracked Polymerase Inhibitor
  - 6.1.19 Tegobuvir (Gilead Sciences): Combination Therapy in Peginterferon-free Regimens
  - 6.1.20 VX-222 (Vertex Pharmaceuticals): Landmark Interferon-Free Drug Regimen
- 6.2 Leading Hepatitis B Pipeline Candidates, 2012
- 6.2.1 Heplisav (Dynavax Technologies): Higher Seroprotection Levels
  - 6.2.2 Rep 9AC' (REPLICor): Targeting Hb Surface Antigens
  - 6.2.3 Myrcludex B (MYR): Dual Effect on Hepatitis B and D
  - 6.2.4 AGX-1009 (Agenix): Tenofovir Prodrug Targeted towards China's Growing Hepatitis Population

## **7. LEADING COMPANIES IN THE HEPATITIS TREATMENTS AND VACCINES MARKET**

- 7.1 Leading Market Players, 2012
- 7.2 Roche
  - 7.2.1 Product Overview and Performance, 2012
  - 7.2.2 Recent Developments: Partnership with Anadys

- 7.2.3 Hepatitis Pipeline
- 7.2.4 Future Outlook: Slowing Demand May Affect Market Dominance
- 7.3 GSK
  - 7.3.1 Product Overview and Performance, 2012
  - 7.3.2 Recent Developments: Increasing Focus on Novel Small Molecule Therapies
  - 7.3.3 Hepatitis Pipeline: Polymerase Inhibitor in Phase II
  - 7.3.4 Future Outlook: Dominance in Vaccines Unmatched
- 7.4 Bristol-Myers Squibb
  - 7.4.1 Product Overview and Performance, 2012
  - 7.4.2 Recent Developments: Strengthening Product Pipeline Through Acquisitions
    - 7.4.2.1 Bristol-Myers Squibb Acquires Inhibitex
  - 7.4.3 Hepatitis Pipeline: Strong Future Position in Hepatitis C
  - 7.4.4 Future Outlook: Market Set For Intense Competition
- 7.5 Merck & Co.
  - 7.5.1 Product Overview and Performance, 2012
  - 7.5.2 Recent Developments: Discovering Combination Treatments Through Roche Partnership
  - 7.5.3 Hepatitis Pipeline
  - 7.5.4 Future Outlook: Company Pins Hopes on Victrelis and Launch of Pipeline Therapies
- 7.6 Vertex Pharmaceuticals
  - 7.6.1 Product Overview and Performance, 2012
  - 7.6.2 Recent Developments
  - 7.6.3 Hepatitis Pipeline: Polymerase Inhibitors in Phase II Trials
  - 7.6.4 Future Outlook: Company Hope Pipeline Will Maintain Market Position
- 7.7 Gilead Sciences
  - 7.7.1 Product Overview and Performance, 2012
  - 7.7.2 Recent Developments: Gilead Acquires Pharmasset
  - 7.7.3 Hepatitis Pipeline: Strong and Diverse
  - 7.7.4 Future Outlook: Strongest Pipeline Than Any Other Company
- 7.8 Novartis
  - 7.8.1 Product Overview and Performance, 2012
  - 7.8.2 Recent Developments: Company Partnerships/Collaborations to Strengthen Position
  - 7.8.3 Hepatitis Pipeline: Improved Cyclophilin Inhibitor in Phase III Trials
  - 7.8.4 Future Outlook
- 7.9 Leading Hepatitis Pipeline Companies, 2012
  - 7.9.1 Abbott Laboratories: New Venture into Hepatitis
  - 7.9.2 Achillion Pharmaceuticals: Next Target for Acquisition?

7.9.2.1 Achillion and Gilead

7.9.3 Boehringer Ingelheim: Focus on Protease/Polymerase Inhibitors

7.9.4 Idenix Pharmaceuticals: Pipeline Drug Receives Fast-Track Status

7.9.4.1 Idenix Pharmaceuticals: Outlook

## **8. HEPATITIS TREATMENTS AND VACCINES MARKET: INDUSTRY TRENDS, 2013-2023**

8.1 Strengths and Weaknesses in the Hepatitis Treatments and Vaccines Market, 2013-2023

8.1.1 Resistance in Hepatitis B

8.1.2 Interferon Therapy Has Drawbacks

8.1.3 Genotype 1: A Common but Difficult to Treat Form of Hepatitis C

8.2 Opportunities and Threats in the Hepatitis Treatments and Vaccines Market, 2013-2023

8.2.1 Hepatitis Screening and Diagnosis

8.2.2 Raising Awareness and Overcoming Social Stigma

8.2.3 Personalised Therapy

8.2.4 HIV Co-Infection

8.2.5 Asia

8.3 STEP Analysis of the World Hepatitis Treatments and Vaccines Market, 2013-2023

8.3.1 Social Development

8.3.1.1 Social Implications in China

8.3.2 Technological Advances

8.3.3 Economic Pressures

8.3.4 Political Issues

8.4 Hepatitis B Vaccination

8.5 Limited Hepatitis B Pipeline

8.6 Hepatitis C Vaccines

8.7 Oral Direct-Acting Antivirals

8.7.1 Nucleoside and Non-Nucleoside Polymerase Inhibitors

8.7.2 Combining Protease and Polymerase Inhibitors

8.7.3 The Need for Ribavirin

8.7.4 Twelve Week Treatment Target

8.8 Pharmaceutical Investment in Hepatitis C

8.8.1 Licensing and Partnering Deals

8.8.2 Acquisitions in Hepatitis C

8.8.3 Future Targets for Collaboration or Acquisition

## **9. RESEARCH INTERVIEW**

9.1 Interview with Mr Carl Stubbings, CBO, Benitec Pharma Ltd.

9.1.1 The Hepatitis C Treatment Market Landscape

9.1.2 TT-034: Cassette Vector for the Treatment of Hepatitis C

9.1.3 The Future Hepatitis Drug Market

## **10. CONCLUSIONS**

10.1 State of the Hepatitis Treatments and Vaccines Market, 2012

10.2 Growth in the Hepatitis Treatments and Vaccines Market, 2013-2023

10.2.1 Rise of Direct-Acting Antivirals in Hepatitis C

10.2.2 Weak Pipeline for Hepatitis B

10.3 Asia as a Hepatitis Drug Market

## List Of Tables

### LIST OF TABLES

Table 1.1 Currency Exchange Rates

Table 1.2 Abbreviations and Acronyms Used in the Report

Table 2.1 Hepatitis Subtypes: An Overview

Table 2.2 Polymerase Inhibitors Approved for Hepatitis B in the US and EU, 2012

Table 3.1 Hepatitis Treatments and Vaccines: Revenue (\$bn) and Market Share (%) by Sector, 2012

Table 3.2 Hepatitis Treatment Market: Revenue (\$bn) and Market Share (%) by Indication, 2012

Table 3.3 Hepatitis Treatments and Vaccines: Overall Market and Revenue Forecasts (\$bn) by Sector, 2013-2023

Table 3.4 Selected Biosimilar Interferon Alpha Therapies Approved in Emerging Markets, 2013

Table 3.5 Oral Antivirals Submarket: Revenue (\$bn) and Market Share (%) by Drug, 2012

Table 3.6 Oral Antivirals Submarket: Revenue Forecast (\$bn), 2013-2023

Table 3.7 Interferons Submarket: Revenue (\$bn) and Market Share (%) by Drug, 2012

Table 3.8 Interferons Submarket: Revenue Forecast (\$bn), 2013-2023

Table 3.9 Vaccines Submarket: Revenue (\$bn) and Market Share (%) by Drug, 2012

Table 3.10 Vaccines Submarket: Revenue Forecast (\$bn), 2013-2023

Table 3.11 Hepatitis Treatments and Vaccines: Revenue (\$bn) and Market Share (%) by Sector in 2012, 2018 and 2023

Table 3.12 Hepatitis Treatment Market: Overall Market and Revenue Forecasts (\$bn) by Indication, 2013-2023

Table 4.1 Chronic Hepatitis B & C: Global Prevalence (millions) by Region, 2012

Table 4.2 Hepatitis Treatments and Vaccines: Revenue (\$bn) and Market Share (%) by Region, 2012

Table 4.3 Hepatitis Treatments and Vaccines: Overall Market and Revenue Forecasts (\$bn) by Region, 2013-2023

Table 4.4 US Hepatitis Treatments and Vaccines: Forecast (\$bn), 2013-2023

Table 4.5 EU5 Hepatitis Treatments and Vaccines: Revenue (\$bn), EU5 Market Share (%) and Global Market Share (%) by Country, 2012

Table 4.6 EU5 Hepatitis Treatments and Vaccines Market: Revenue Forecasts (\$bn) by Country, 2013-2023

Table 4.7 Italian Hepatitis Treatments and Vaccines: Forecast (\$bn), 2013-2023

Table 4.8 Spanish Hepatitis Treatments and Vaccines: Forecast (\$bn), 2013-2023

Table 4.9 German Hepatitis Treatments and Vaccines: Forecast (\$bn), 2013-2023

Table 4.10 UK Hepatitis Treatments and Vaccines: Forecast (\$bn), 2013-2023

Table 4.11 French Hepatitis Treatments and Vaccines: Forecast (\$bn), 2013-2023

Table 4.12 Chinese Hepatitis Treatments and Vaccines: Forecast (\$bn), 2013-2023

Table 4.13 Japanese Hepatitis Treatments and Vaccines: Forecast (\$bn), 2013-2023

Table 4.14 Indian Hepatitis Treatments and Vaccines: Forecast (\$bn), 2013-2023

Table 4.15 Russian Hepatitis Treatments and Vaccines: Forecast (\$bn), 2013-2023

Table 4.16 Brazilian Hepatitis Treatments and Vaccines: Forecast (\$bn), 2013-2023

Table 5.1 Baraclude: Key Facts, 2012

Table 5.2 Baraclude: Revenue (\$bn) by Region, 2010-2012

Table 5.3 Baraclude: Revenue Forecast (\$bn), 2013-2023

Table 5.4 Zeffix: Key Facts, 2012

Table 5.5 Zeffix: Revenue (\$bn) by Region, 2011-2012

Table 5.6 Zeffix: Revenue Forecast (\$bn), 2013-2023

Table 5.7 Hepsera: Key Facts, 2012

Table 5.8 Hepsera: Revenue (\$bn) by Company, 2010-2012

Table 5.9 Hepsera: Revenue Forecast (\$bn), 2013-2023

Table 5.10 Viread: Key Facts, 2012

Table 5.11 Viread: Revenue Forecast (\$bn), 2013-2023

Table 5.12 Tyzeka: Key Facts, 2012

Table 5.13 Tyzeka: Revenue Forecast (\$bn), 2013-2023

Table 5.14 GSK's Hepatitis Vaccines: Key Facts, 2012

Table 5.15 Engerix-B/Havrix/Twinrix/Fendrix: Revenue (\$bn) and Market Share (%) by Region, 2012

Table 5.16 Engerix-B/Havrix/Twinrix/Fendrix: Revenue Forecast (\$bn), 2013-2023

Table 5.17 Pegasys: Key Facts, 2012

Table 5.18 Pegasys: Revenue Forecast (\$bn), 2013-2023

Table 5.19 Incivek: Key Facts, 2012

Table 5.20 Incivek: Revenue (\$bn) and Market Share (%) by Region, 2012

Table 5.21 Incivek: Revenue Forecast (\$bn), 2013-2023

Table 5.22 PegIntron: Key Facts, 2012

Table 5.23 PegIntron: Revenue Forecast (\$bn), 2013-2023

Table 5.24 Victrelis: Key Facts, 2012

Table 5.25 Victrelis: Revenue Forecast (\$bn), 2013-2023

Table 6.1 Selected Hepatitis C Pipeline Candidates in Phase II & III, 2012

Table 6.2 Alisporivir: Phase III Trials, 2012

Table 6.3 Selected Hepatitis B Pipeline Candidates in Clinical Trials, 2012

Table 7.1 Hepatitis Treatments and Vaccines: Revenue (\$bn) and Market Share (%) by Company, 2012



Table 7.2 Roche: Hepatitis Pipeline, 2012

Table 7.3 Pegasys: Revenue (\$bn) and Market Share (%) in 2012, 2018 and 2023

Table 7.4 GSK Pharmaceuticals: Revenue (\$bn) and Market Share (%) by Therapeutic Area, 2012

Table 7.5 Bristol-Myers Squibb: Hepatitis Pipeline, 2012

Table 7.6 Merck & Co: Revenue (\$bn) and Market Share (%) by Therapeutic Area, 2012

Table 7.7 Telaprevir: Revenue (\$bn) by Trade Name, 2012

Table 7.8 Gilead Sciences: Revenue (\$bn) and Market Share (%) by Therapeutic Area, 2012

Table 7.9 Gilead Sciences: Hepatitis Pipeline, 2012

Table 7.10 Achillion Pharmaceuticals: Hepatitis Pipeline, 2012

Table 7.11 Idenix Pharmaceuticals: Hepatitis Pipeline, 2012

Table 8.1 Hepatitis Treatments and Vaccines Market: Strengths and Weaknesses, 2013

Table 8.2 Hepatitis Treatments and Vaccines Market: Opportunities and Threats, 2013-2023

Table 8.3 Liver Cancer: Global Deaths (per 100,000) by Region, 2008

Table 8.4 Selected Pipeline Drugs Granted Fast Track Status, 2011-2012

Table 8.5 Selected All-Oral Hepatitis C Regimens in Development, 2012

Table 8.6 Market Capitalisation of Selected Hepatitis Drug Developers, 2012

Table 10.1 Hepatitis Treatments and Vaccines: Revenue (\$bn) by Drug & Sector in 2012, 2018 & 2023

Table 10.2 Leading Hepatitis Treatments: Patent Expiries & Peak Revenues (\$bn)

## About

### **Lack of Differentiation and Competition Affecting Market Share**

The oral polymerase inhibitor sector of the hepatitis B market is highly competitive, with five leading brands available in major markets worldwide. Tyzeka was the fourth of these to be approved and, it currently struggles to compete in terms of market share. This is reportedly owing to its resistance profile, which mirrors that of other products that have been available on the market for longer, meaning there is little clear differentiation from other drugs. Additionally, its resistance profile means that under current regulatory guidelines, Tyzeka is not recommended as a first-line therapy for hepatitis B. However, unlike Viread, Tyzeka is available in China, having been approved there in March 2007.

### **Tyzeka: Revenue Forecast, 2013-2023**

In spite of the drug's resistance, visiongain anticipates growth in Tyzeka's revenue for the early forecast period of this report, due to increased uptake in all markets worldwide. However, the lack of competitiveness in comparison to other oral antivirals, particularly those approved around the same time as Tyzeka, mean that it will struggle to achieve high revenues. The resistance profile of Tyzeka is weaker than that for Baraclude and Viread, visiongain notes. Therefore the rate of revenue growth will fall towards patent expiry for the drug in 2020. Peak revenue will be \$0.11bn in 2020. Between 2012 and 2018, Tyzeka's revenue will grow with a CAGR of 9.9%. The continued demand for oral antivirals in treating hepatitis B, given the lack of novel drugs in the pipeline, will drive this growth. By 2023, however, revenue will have fallen to \$0.06bn, visiongain predicts.

## I would like to order

Product name: Hepatitis Drugs and Vaccines: World Market 2013-2023

Product link: <https://marketpublishers.com/r/H0F51E5D826EN.html>

Price: US\$ 2,635.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H0F51E5D826EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970